{"id":53597,"date":"2023-09-20T09:48:06","date_gmt":"2023-09-20T09:48:06","guid":{"rendered":"https:\/\/medsname.com\/votrient\/"},"modified":"2026-04-30T10:25:11","modified_gmt":"2026-04-30T10:25:11","slug":"votrient","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/votrient\/","title":{"rendered":"Votrient"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Votrient?<\/h3>\n<p style=\"margin:0;\"><strong>Votrient<\/strong> este un comprimat oral de la Novartis care con\u021bine <strong>pazopanib 400 mg<\/strong> \u2014 un inhibitor multivalent de tirozin-kinaz\u0103 (VEGFR-1\/2\/3, PDGFR-\u03b1\/-\u03b2, KIT) pentru <strong>carcinomul renal avansat (RCC)<\/strong> \u0219i <strong>sarcoma avansat de \u021besuturi moi<\/strong> (dup\u0103 chimioterapie anterioar\u0103). Doz\u0103 standard: <strong>800 mg o dat\u0103 pe zi pe stomac gol<\/strong> (1 or\u0103 \u00eenainte sau 2 ore dup\u0103 mese). <strong>Avertizare hepatotoxicitate (black-box)<\/strong> \u2014 leziuni hepatice severe, uneori fatale. Monitorizarea obligatorie a testelor hepatice (LFT) s\u0103pt\u0103m\u00e2nal \u00een primele 9 s\u0103pt\u0103m\u00e2ni, apoi lunar. Alte riscuri importante: hipertensiune (~40%), diaree, oboseal\u0103, modificarea culorii p\u0103rului (depigmentare), proteinurie, prelungire QT, evenimente trombotice arteriale, perfora\u021bie gastrointestinal\u0103, afectarea cicatriz\u0103rii r\u0103nilor.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;\"><strong>\u26a0 Supraveghere specializat\u0103 necesar\u0103.<\/strong> Medicamentele pentru cancer trebuie prescrise de un oncolog tratant, cu un diagnostic confirmat, stadializare ini\u021bial\u0103 \u0219i un plan de tratament definit. Nu \u00eencepe\u021bi, nu opri\u021bi, nu modifica\u021bi doza \u0219i nu utiliza\u021bi medicamente pentru cancer \u00een afara unui plan de \u00eengrijire condus de oncologie. Majoritatea medicamentelor pentru cancer necesit\u0103 monitorizare regulat\u0103 prin analize de s\u00e2nge (hemoleucogram\u0103, teste hepatice, func\u021bie renal\u0103), sunt absolut contraindicate \u00een sarcin\u0103 \u0219i au interac\u021biuni medicamentoase semnificative.<\/div>\n<div style=\"background:#f4f8fb;border:1px solid #d6e4ec;padding:12px 18px;margin:14px 0;border-radius:4px;font-size:14px;color:#3a5160;text-align:center;\">\n<strong>\ud83d\udd12 Checkout criptat<\/strong> \u00b7 <strong>\ud83d\udcb3 Procesor verificat<\/strong> \u00b7 <strong>\ud83d\ude9a Livrare worldwide<\/strong> \u00b7 <strong>\u2b50 4,9\/5 de la peste 1.400 de clien\u021bi<\/strong>\n<\/div>\n<h2 class=\"wp-block-heading\">Ce este Votrient?<\/h2>\n<p>Votrient este un comprimat oral de la Novartis care con\u021bine <strong>pazopanib 400 mg<\/strong>. Pazopanibul este un inhibitor multivalent de tirozin-kinaz\u0103 activ \u00eempotriva VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-\u03b1, PDGFR-\u03b2, FGFR-1 \u0219i KIT. Prin blocarea semnaliz\u0103rii vasculare \u0219i a factorilor de cre\u0219tere, inhib\u0103 angiogeneza tumoral\u0103 \u0219i cre\u0219terea \u00een tumorile vasculare.<\/p>\n<h2 class=\"wp-block-heading\">Utiliz\u0103ri \u0219i indica\u021bii<\/h2>\n<ul>\n<li><strong>Carcinom renal avansat (RCC)<\/strong> \u2014 de prim\u0103 linie \u0219i dup\u0103 terapie cu citokine<\/li>\n<li><strong>Sarcoma avansat de \u021besuturi moi (STS)<\/strong> \u2014 dup\u0103 chimioterapie anterioar\u0103 (studiul PALETTE)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Doza \u0219i mod de administrare<\/h2>\n<p>Doza standard: <strong>800 mg o dat\u0103 pe zi (2 comprimate de 400 mg) pe stomac gol<\/strong> \u2014 1 or\u0103 \u00eenainte sau 2 ore dup\u0103 orice mas\u0103. Alimentele cresc absorb\u021bia pazopanibului de ~2 ori, cresc\u00e2nd riscul de toxicitate.<\/p>\n<ol>\n<li><strong>Stomacul gol \u2014 obligatoriu.<\/strong> Stabile\u0219te o rutin\u0103: administreaz\u0103 doza cu 1 or\u0103 \u00eenainte de micul dejun, SAU cu 2 ore dup\u0103 cin\u0103, \u00eenainte de culcare.<\/li>\n<li>\u00cenghite comprimatele \u00eentregi \u2014 nu le zdrobi, dizolva sau despica (modificare semnificativ\u0103 a absorb\u021biei).<\/li>\n<li><strong>Monitorizare obligatorie:<\/strong> Teste hepatice la \u00eenceput, apoi <strong>s\u0103pt\u0103m\u00e2nal pentru primele 9 s\u0103pt\u0103m\u00e2ni<\/strong>, apoi lunar. Tensiunea arterial\u0103 la \u00eenceput + la fiecare 1\u20132 s\u0103pt\u0103m\u00e2ni pentru primele 6 s\u0103pt\u0103m\u00e2ni, apoi lunar. ECG (QTc) la \u00eenceput + la 4\u20136 s\u0103pt\u0103m\u00e2ni. Analize de urin\u0103 pentru proteinurie lunar. Teste tiroidiene la fiecare 3 luni.<\/li>\n<li>Modific\u0103ri de dozaj: reduce\u021bi cu incremente de 200\u2013400 mg pentru toxicitate grad \u2265 3, AST\/ALT &gt; 8\u00d7 ULN, hipertensiune sever\u0103, proteinurie sever\u0103 sau prelungire QT.<\/li>\n<li>Suspend\u0103 pazopanib cu 7\u201314 zile \u00eenainte de interven\u021bia chirurgical\u0103 electiv\u0103; reluare la 2\u20134 s\u0103pt\u0103m\u00e2ni dup\u0103 vindecarea complet\u0103 a r\u0103nii.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<p><strong>Frecvente:<\/strong> diaree, oboseal\u0103, grea\u021b\u0103, sc\u0103derea apetitului, pierdere \u00een greutate, schimbare \u00een culoarea p\u0103rului (depigmentare), hipertensiune, sindrom m\u00e2n\u0103-picior, modificarea gustului, mucozit\u0103.<\/p>\n<p><strong>Important:<\/strong><\/p>\n<ul>\n<li><strong>Hepatotoxicitate (AVERTIZARE BLACK BOX)<\/strong> \u2014 leziuni hepatice severe, uneori fatale. Majoritatea cazurilor \u00een primele 4\u20139 s\u0103pt\u0103m\u00e2ni. Monitorizare obligatorie a testelor hepatice.<\/li>\n<li>Hipertensiune arterial\u0103 (~40%) \u2014 de nou\u0103 apari\u021bie sau agravare; trata\u021bi agresiv<\/li>\n<li>Prelungirea intervalului QT \u0219i torsade de pointes<\/li>\n<li>Evenimente trombotice arteriale (IM, AVC, AIT)<\/li>\n<li>Hemoragii (epistaxis, GI, intracraniene)<\/li>\n<li>Perfora\u021bie GI \u0219i fistul\u0103<\/li>\n<li>Proteinurie, sindrom nefrotic<\/li>\n<li>Hipotiroidism<\/li>\n<li>Sindromul de leucoencefalopatie posterioar\u0103 reversibil\u0103 (PRES)<\/li>\n<li>Vindecare \u00eent\u00e2rziat\u0103 a r\u0103nilor<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Avertismente<\/h2>\n<ul>\n<li><strong>Sarcina:<\/strong> teratogen. Contraceptie fiabil\u0103 pe tot parcursul tratamentului + 2 s\u0103pt\u0103m\u00e2ni dup\u0103.<\/li>\n<li><strong>Insuficien\u021b\u0103 hepatic\u0103 sever\u0103 (Child-Pugh C):<\/strong> contraindicated.<\/li>\n<li><strong>Prelungire QT, anomalii electrolitice:<\/strong> corecta\u021bi hipokaliemia\/hipomagnezemia \u00eenainte de \u00eencepere.<\/li>\n<li><strong>Eveniment trombolic arterial recent (&lt; 6 luni):<\/strong> evita\u021bi.<\/li>\n<li><strong>Interven\u021bie chirurgical\u0103:<\/strong> suspendare 7\u201314 zile \u00eenainte; reluare dup\u0103 2\u20134 s\u0103pt\u0103m\u00e2ni.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;\">Combina\u021bi cu<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Efect<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Ce s\u0103 face\u021bi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Inhibitori puternici ai CYP3A4 (ketoconazol, ritonavir, claritromicin\u0103)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Cre\u0219te nivelul de pazopanib \u2014 toxicitate<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce\u021bi doza de pazopanib la 400 mg\/zi dac\u0103 este inevitabil.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Inductori puternici ai CYP3A4 (rifampicin\u0103, fenitoin\u0103, carbamazepin\u0103, Hypericum perforatum)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Sc\u0103derea nivelului de pazopanib \u2014 e\u0219ec terapeutic<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Evita\u021bi.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">IPB (omeprazol, esomeprazol, pantoprazol)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce absorb\u021bia de pazopanib \u00een mod substan\u021bial \u2014 e\u0219ec terapeutic<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Comuta\u021bi la blocant H2 cu ac\u021biune scurt\u0103; separa\u021bi administrarea dac\u0103 este necesar un blocant H2.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Medicamente care prelungesc intervalul QT (citalopram, ondansetron, fluorochinolone, metadon\u0103)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Prelungire QT aditiv\u0103<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Evita\u021bi combina\u021biile; monitorizare ECG.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Warfarin<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Risc de s\u00e2ngerare; variabilitate INR<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Monitoriza\u021bi INR s\u0103pt\u0103m\u00e2nal la \u00eenceput.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Suc de grapefruit<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Cre\u0219te nivelul de pazopanib<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Evita\u021bi.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<ul>\n<li>Temperatur\u0103 ambient\u0103, 15\u201325\u00b0C, \u00een blisterul original.<\/li>\n<li>Depozita\u021bi \u00een afara accesului copiilor, femeilor \u00een v\u00e2rst\u0103 de reproducere, animalelor de companie.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Alternative conexe pe MedsBase<\/h2>\n<p>Alte medicamente oncologice disponibile \u00eempreun\u0103 cu acest produs:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/imat\/\"><strong>Imat (imatinib 400 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/imatib\/\"><strong>Imatib (imatinib 100 \/ 400 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/veenat\/\"><strong>Veenat (imatinib 100 mg)<\/strong><\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/medsbase.com\/ro\/anti-cancer-medication\/\">R\u0103sfoi\u021bi toate medicamentele anti-cancer \u2192<\/a><\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">De ce trebuie s\u0103 iau Votrient pe stomacul gol?<\/h3>\n<p>Alimentele (\u00een special cele bogate \u00een gr\u0103simi) pot <strong>dubla absorb\u021bia de pazopanib<\/strong>, cresc\u00e2nd concentra\u021bia sanguin\u0103 p\u00e2n\u0103 \u00een intervalul toxic \u0219i major\u00e2nd riscul de hepatotoxicitate, hipertensiune \u0219i prelungire a intervalului QT. Lua\u021bi 1 or\u0103 \u00eenainte de orice mas\u0103 SAU 2 ore dup\u0103 ultima mas\u0103. Majoritatea pacien\u021bilor consider\u0103 cel mai u\u0219or s\u0103 ia pazopanib chiar \u00eenainte de culcare (presupun\u00e2nd c\u0103 cina s-a terminat cu \u2265 2 ore \u00eenainte) sau diminea\u021ba, imediat dup\u0103 trezire.<\/p>\n<h3 class=\"wp-block-heading\">De ce Votrient este asociat cu hepatotoxicitate sever\u0103?<\/h3>\n<p>Pazopanib poart\u0103 un avertisment FDA <strong>de tip black-box pentru leziuni hepatice severe, uneori fatale<\/strong>. Majoritatea cazurilor apar \u00een primele 4\u20139 s\u0103pt\u0103m\u00e2ni. Monitorizare obligatorie: teste de func\u021bie hepatic\u0103 la ini\u021biere, apoi <strong>s\u0103pt\u0103m\u00e2nal \u00een primele 9 s\u0103pt\u0103m\u00e2ni<\/strong>, apoi lunar. \u00centrerupe\u021bi pazopanib imediat pentru AST\/ALT &gt; 8\u00d7 ULN sau pentru orice simptom de leziune hepatic\u0103 (icter, urin\u0103 \u00eenchis\u0103, oboseal\u0103 sever\u0103).<\/p>\n<h3 class=\"wp-block-heading\">De ce culoarea p\u0103rului se schimb\u0103 la tratamentul cu Votrient?<\/h3>\n<p>Pazopanib inhib\u0103 tirosinaza (implicat\u0103 \u00een sinteza melaninei) ca efect secundar. Depigmentarea p\u0103rului \u2014 adesea dramatic\u0103, uneori transform\u00e2nd p\u0103rul alb sau gri \u00een c\u00e2teva luni \u2014 este reversibil\u0103 la \u00eentreruperea tratamentului. Afecteaz\u0103 ~40% din pacien\u021bi. Doar cosmetic, f\u0103r\u0103 semnifica\u021bie clinic\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Cum se gestioneaz\u0103 hipertensiunea arterial\u0103?<\/h3>\n<p>Hipertensiunea indus\u0103 de pazopanib este mecanistic\u0103 (inhibi\u021bia VEGF reduce sinteza oxidului nitric). Afecteaz\u0103 ~40% din pacien\u021bi, adesea \u00een primele 6 s\u0103pt\u0103m\u00e2ni. Tratament agresiv: inhibitor ACE sau ARB la prima linie (ramipril, losartan, candesartan), ad\u0103uga\u021bi CCB sau diuretic dac\u0103 este necesar. Evita\u021bi \u00eentreruperea pazopanibului din cauza hipertensiunii dac\u0103 TA poate fi controlat\u0103 \u2014 hipertensiunea coreleaz\u0103 de fapt cu eficacitatea antitumoral\u0103.<\/p>\n<h3 class=\"wp-block-heading\">De ce trebuie s\u0103 \u00eentrerup Votrient \u00eenainte de opera\u021bie?<\/h3>\n<p>Pazopanib afecteaz\u0103 cicatrizarea (angiogeneza mediat\u0103 de VEGF este esen\u021bial\u0103 pentru repararea pl\u0103gilor) \u0219i cre\u0219te riscul de s\u00e2ngerare. \u00centrerupe\u021bi <strong>7\u201314 zile \u00eenainte de opera\u021bia programat\u0103<\/strong>. Relua\u021bi numai dup\u0103 ce plaga chirurgical\u0103 este complet vindecat\u0103, de obicei <strong>2\u20134 s\u0103pt\u0103m\u00e2ni postoperator<\/strong>. Spune\u021bi fiec\u0103rui chirurg \u0219i dentist despre pazopanib.<\/p>\n<h3 class=\"wp-block-heading\">Pot lua un PPI cu Votrient?<\/h3>\n<p>PPI-urile (omeprazol, pantoprazol, esomeprazol) cresc pH-ul gastric \u0219i reduc substan\u021bial absorb\u021bia pazopanibului \u2014 risc\u00e2nd e\u0219ecul tratamentului. Trece\u021bi la un blocant H2 cu ac\u021biune scurt\u0103 (famotidin\u0103) \u0219i separa\u021bi administrarea cu 2+ ore, SAU folosi\u021bi antiacid doar c\u00e2nd simptomatic, separat cu 2+ ore de pazopanib.<\/p>\n<h3 class=\"wp-block-heading\">Pot consuma alcool cu Votrient?<\/h3>\n<p>Limita\u021bi alcoolul \u2014 at\u00e2t alcoolul c\u00e2t \u0219i pazopanibul sunt hepatotoxice \u0219i combina\u021bia amplific\u0103 riscul de leziuni hepatice severe. Cantit\u0103\u021bi mici ocazionale pot fi tolerabile, dar consumul zilnic sau excesiv ar trebui evitat.<\/p>\n<h3 class=\"wp-block-heading\">Votrient \u00eemi va vindeca cancerul?<\/h3>\n<p>Pazopanib nu este \u00een general vindec\u0103tor pentru cancerul renal avansat (RCC) sau sarcom, dar produce un control semnificativ al bolii. \u00cen RCC, supravie\u021buirea medie f\u0103r\u0103 progresie la prima linie cu pazopanib este de aproximativ 11 luni (studiu COMPARZ). \u00cen sarcoma dup\u0103 chimioterapie, prelungirea PFS este mai modest\u0103. Tratamentul continu\u0103 p\u00e2n\u0103 la progresie sau toxicitate inacceptabil\u0103. Noile combina\u021bii de imunoterapie (pembrolizumab + axitinib, nivolumab + cabozantinib) au \u00eenlocuit \u00een mare m\u0103sur\u0103 monoterapia cu pazopanib pentru RCC la prima linie acolo unde sunt disponibile.<\/p>\n<p><!-- medsbase-why-order --><\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Fiecare lot este procurat de la un <strong>produc\u0103tor certificat WHO-GMP<\/strong>. Comenzile sunt expediate \u00een ambalaje simple, f\u0103r\u0103 marc\u0103, de la partenerii no\u0219tri de onorare \u0219i acoperite de <a href=\"\/ro\/medsbase-re-shipment-assurance-policy\/\">Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>: dac\u0103 un colet nu ajunge \u00een 20 de zile lucr\u0103toare, trimitem gratuit o nou\u0103 comand\u0103, f\u0103r\u0103 \u00eentreb\u0103ri.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Medicamente Anticanceroase Asem\u0103n\u0103toare<\/h3>\n<p>Alte medicamente oncologice disponibile \u00eempreun\u0103 cu acest produs:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/imatib\/\">Imatib (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/veenat\/\">Veenat (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/imat\/\">Imat (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/riborea\/\">Riborea (ribociclib 200 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/keytruda\/\">Keytruda (pembrolizumab 100 mg)<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Inhib\u0103 cre\u0219terea celulelor canceroase<br \/>\n\u2705 Trateaz\u0103 cancerul renal avansat<br \/>\n\u2705 Gestioneaz\u0103 sarcoma de \u021besut moale<br \/>\n\u2705 \u00cencetine\u0219te progresia tumorii<br \/>\n\u2705 Convenien\u021ba administr\u0103rii orale<\/p>","protected":false},"featured_media":53598,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53597","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/53597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=53597"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/53598"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=53597"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=53597"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=53597"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=53597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}